Home - Translational Lung Cancer Research

Translational Lung Cancer Research to publish monthly beginning in January 2021

Since its initiation in 2012, Translational Lung Cancer Research (TLCR) has been developing at a speedy pace with increasing readership and citations. In order to better serve the growing needs of readers and authors, the TLCR will move from a bimonthly to a monthly publication schedule beginning in January 2021.

Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions

A deeper understanding of innate/acquired resistance to the different TKIs already available for clinical use and the development of new effective treatment strategies to overcome it, represent a current area of intense investigation and has been extensively debated within different papers published in the series.

Lung Cancer Multidisciplinary Care

The papers in this series explore important aspects of MDT care including the early introduction of palliative care, the impact on advanced disease, optimal staging in the context of the MDT, gaps in our understanding of how to best implement and test the effects of MDTs, patient outcomes associated with MDT care, lung cancer surgery in the MDT setting and optimized approaches to data systems for the MDT.

New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies

During the last decade we have seen many changes in the field of Lung Pathology, and had to keep with the immense progress: new therapy options for lung cancer patients have changed our practice and required to learn from disciplines such as genetics and immunology. The aim of this series is to discuss new developments or already present techniques and confront pathologists with this news, hopefully convincing them to adjust the daily practice accordingly.

New Impact Factor for Translational Lung Cancer Research: 5.132

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2019 citation year: 5.132.

AME entered an official partnership with Publons to enhance wide-ranging recognition for reviewers

AME Publishing Company entered an official partnership with Publons, a product of Clarivate Analytic Company (which owns Web of Science, EndNote, ScholarOne, among many others), as of April 2020. Around 60 AME journals’ peer review systems are now integrated seamlessly into the Publons platform (https://publons.com/about/home). The partnership was done to recognize our expert peer reviewers spontaneously for their review contribution.

Implementation of transparent peer review at Translational Lung Cancer Research

With a commitment to openness and accountability, and to increase the level of transparency throughout our peer review process, our editorial office has decided to implement a transparent peer review process as an option for all manuscripts submitted to TLCR from March 18, 2020.

TLCR Annual Report 2019

In the past 2019, Translational Lung Cancer Research made great progress on publication quality and quantity in view of its publication number, pageviews, citations and PubMed retrievals. Furthermore, TLCR has published a series of high-quality focused issues guest-edited by a number of excellent experts who have been actively involved in the forefront of scientific research and clinical practice.

‹ ›

Vol 9, No 6 (December, 2020)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

Editorial

Cyclin D1 expression in KRAS mutant non-small cell lung cancer—old wine into new skins

Kah Yee Goh, Wan-Teck Lim

PDF Pages: 2302-2304 Full Text COI Form Open Access

The gut microbiome and its interaction with health, disease, treatment response and toxicity in patients advanced cancer: focus on lung cancer and immunotherapy

Nadina Tinsley, Natalie Cook

PDF Pages: 2305-2307 Full Text COI Form Open Access

Radiomics signature for prediction of N2 disease: fascinating but still a long way to go for clinical application

Kwon Joong Na, Hongyoon Choi, Young Tae Kim

PDF Pages: 2308-2310 Full Text COI Form Open Access

Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?

Ramon Andrade De Mello, Jin-Hui Zhu, Jairo Iavelberg, Artur Henrique Potim, Débora Simonetti, José Antônio Silva Jr, Pedro Castelo-Branco, Daniel Humberto Pozza, Carla Chizuru Tajima, Maria Tolia, Georgio Antoniou

PDF Pages: 2311-2314 Full Text COI Form Open Access

Original Article

Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation

Yishan Yu, Linlin Wang, Shufen Cao, Siming Gao, Weili Wang, Lianne Mulvihill, Mitchell Machtay, Pingfu Fu, Jinming Yu, Feng-Ming (Spring) Kong

PDF Pages: 2315-2327 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease

Yuanjun Liu, Yaoyao Zhu, Ran Wu, Min Hu, Lingnan Zhang, Qingren Lin, Denghu Weng, Xiaojiang Sun, Yu Liu, Yaping Xu

PDF Pages: 2328-2336 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2

Sha Huang, Tianyu He, Sijia Yang, Hongxu Sheng, Xiuwen Tang, Feichao Bao, Yiqing Wang, Xu Lin, Wenfeng Yu, Fei Cheng, Wang Lv, Jian Hu

PDF Pages: 2337-2355 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma

Yutao Liu, Yu Feng, Ting Hou, Analyn Lizaso, Feng Xu, Puyuan Xing, Hongyu Wang, Qiaolin Kang, Lu Zhang, Yuankai Shi, Xingsheng Hu

PDF Pages: 2356-2366 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy

Yanjun Xu, Hui Li, Zhiyu Huang, Kaiyan Chen, Xiaoqing Yu, Jiamin Sheng, Han-Han Zhang, Yun Fan

PDF Pages: 2367-2367 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

The feasibility of navigation bronchoscopy-guided pulmonary microcoil localization of small pulmonary nodules prior to thoracoscopic surgery

Junxiang Chen, Xufeng Pan, Chuanjia Gu, Xiaoxuan Zheng, Haibin Yuan, Jun Yang, Jiayuan Sun

PDF Pages: 2380-2390 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer

Xiangwei Ge, Zhibo Zhang, Sujie Zhang, Fang Yuan, Fan Zhang, Xiang Yan, Xiao Han, Junxun Ma, Lijie Wang, Haitao Tao, Xiaoyan Li, Xiaoyu Zhi, Zhiyue Huang, Paul Hofman, Arsela Prelaj, Giuseppe Luigi Banna, Luciano Mutti, Yi Hu, Jinliang Wang

PDF Pages: 2391-2400 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study

Ziqing Zeng, Bo Yan, Yulong Chen, Lianmin Zhang, Jianquan Zhu, Fan Yang, Feng Wei, Terence Chi Chun Tam, Diego Kauffmann-Guerrero, Ross Andrew Soo, Xiubao Ren, Jian You

PDF Pages: 2401-2410 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Hsa_circ_0006571 promotes spinal metastasis through sponging microRNA-138 to regulate sirtuin 1 expression in lung adenocarcinoma

Hou-Lei Wang, Hui-Ren Wang, Yun Liang, An-Nan Hu, Francisco J. Enguita, Xiao-Gang Zhou, Jian Dong

PDF Pages: 2411-2427 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)

Tongji Xie, Yan Li, Jianming Ying, Weijing Cai, Junling Li, Kye Young Lee, Biagio Ricciuti, Jose Pacheco, Puyuan Xing

PDF Pages: 2428-2439 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

The protective effects of granulocyte-macrophage colony-stimulating factor against radiation-induced lung injury

Dan Hu, Yan Zhang, Ruiqi Cao, Yuying Hao, Xiaoye Yang, Tiantian Tian, Jiandong Zhang

PDF Pages: 2440-2459 Full Text Reporting Checklist Data Sharing Statement COI Form Open Access

Protocol

Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study

Bin Qiu, Gaofeng Li, Feng Luo, Xiaohong Cai, Lin Wu, Jianhua Chen, Yanping Hu, Zhiliu Tang, Shuo Yang, Jie He

PDF Pages: 2460-2468 Full Text COI Form Open Access

Review Article

A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia

Ranpu Wu, Chuling Li, Zimu Wang, Hang Fan, Yong Song, Hongbing Liu

PDF Pages: 2469-2478 Full Text Reporting Checklist COI Form Open Access

A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player

Yue Zhou, Fan Yu, Yang Zhao, Ya Zeng, Xi Yang, Li Chu, Xiao Chu, Yida Li, Liqing Zou, Tiantian Guo, Zhengfei Zhu, Jianjiao Ni

PDF Pages: 2479-2493 Full Text Reporting Checklist COI Form Open Access

Case Report

Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report

Xuan Wu, Hanqiong Zhou, Zhen He, Zhe Zhang, Wen Feng, Jiuzhou Zhao, Haiyang Chen, Shuai Wang, Wei Wang, Qiming Wang

PDF Pages: 2494-2499 Full Text Reporting Checklist COI Form Open Access

A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer

Xinyan Xu, Di Liu, Junmiao Wen, Jiayan Chen, Min Fan

PDF Pages: 2500-2507 Full Text Reporting Checklist COI Form Open Access

Editorial Commentary

Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”

Wickii T. Vigneswaran, Muaiad Kittaneh

PDF Pages: 2508-2510 Full Text COI Form Open Access

Perspective of gene therapy with replication competent viruses

Makoto Maemondo

PDF Pages: 2511-2513 Full Text COI Form Open Access

Letter to the Editor

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases

Tao Jiang, Xiaobo Xu, Xiaojuan Chen, Ning Ding, Qin Hu, Caicun Zhou, Jie Hu

PDF Pages: 2514-2517 Full Text Peer Review File COI Form Open Access

Editorial on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions¹

Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?

Francesco Passiglia, Silvia Novello

PDF Pages: 2518-2520 Full Text COI Form Open Access

Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions¹

How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)

Bing Xia, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou, Ross A. Soo

PDF Pages: 2521-2534 Full Text Peer Review File COI Form Open Access

How selecting best therapy for metastatic NTRK fusion-positive non-small cell lung cancer?

Simon Ekman

PDF Pages: 2535-2544 Full Text Peer Review File COI Form Open Access

Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won

Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V. Scagliotti

PDF Pages: 2545-2556 Full Text COI Form Open Access

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer

Ibiayi Dagogo-Jack, Lauren L. Ritterhouse

PDF Pages: 2557-2570 Full Text COI Form Open Access

Decade in review: a new era for RET-rearranged lung cancers

Noura J. Choudhury, Alexander Drilon

PDF Pages: 2571-2580 Full Text COI Form Open Access

Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies

Alessandro Russo, Andrés F. Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo

PDF Pages: 2581-2598 Full Text COI Form Open Access

Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?

Janna Josephus Anna Oda Schoenmaekers, Marthe Sentijna Paats, Anne-Marie Clasina Dingemans, Lizza Elisabeth Lucia Hendriks

PDF Pages: 2599-2617 Full Text COI Form Open Access

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy

Kenichi Suda, Tetsuya Mitsudomi

PDF Pages: 2618-2628 Full Text COI Form Open Access

Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Francesca Bersani, Deborah Morena, Francesca Picca, Alessandro Morotti, Fabrizio Tabbò, Paolo Bironzo, Luisella Righi, Riccardo Taulli

PDF Pages: 2629-2644 Full Text COI Form Open Access

Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas

Matthias S. Matter, Obinna Chijioke, Spasenija Savic, Lukas Bubendorf

PDF Pages: 2645-2655 Full Text Reporting Checklist Peer Review File COI Form Open Access

Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review

Ana Ortega-Franco, Virginia Calvo, Fabio Franco, Mariano Provencio, Raffaele Califano

PDF Pages: 2656-2673 Full Text Reporting Checklist Peer Review File COI Form Open Access

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello

PDF Pages: 2674-2685 Full Text Reporting Checklist Peer Review File COI Form Open Access

How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease

Lorenza Landi, Federico Cappuzzo

PDF Pages: 2686-2695 Full Text Reporting Checklist COI Form Open Access

Consensus

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer

Wenhua Liang, Kaican Cai, Chun Chen, Haiquan Chen, Qixun Chen, Junke Fu, Jian Hu, Tao Jiang, Wenjie Jiao, Shuben Li, Changhong Liu, Deruo Liu, Wei Liu, Yang Liu, Haitao Ma, Xiaojie Pan, Guibin Qiao, Hui Tian, Li Wei, Yi Zhang, Song Zhao, Xiaojing Zhao, Chengzhi Zhou, Yuming Zhu, Ran Zhong, Feng Li, Rafael Rosell, Mariano Provencio, Erminia Massarelli, Mara B. Antonoff, Toyoaki Hida, Marc de Perrot, Steven H. Lin, Massimo Di Maio, Antonio Rossi, Dirk De Ruysscher, Robert A. Ramirez, Wolfram C. M. Dempke, D. Ross Camidge, Nicolas Guibert, Raffaele Califano, Qi Wang, Shengxiang Ren, Caicun Zhou, Jianxing He

PDF Pages: 2696-2715 Full Text COI Form Open Access

Disclosure:

1. The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Silvia Novello and Francesco Passiglia served as the unpaid Guest Editors for the series.

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

An immune-related gene expression signature predicts brain metastasis in lung adenocarcinoma patients after surgery: gene expression profile and immunohistochemical analyses

Young Wha Koh, Jae-Ho Han, Seokjin Haam, Hyun Woo Lee

Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis

Birgitte Sandfeld-Paulsen, Ninna Aggerholm-Pedersen, Anne Winther-Larsen

A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer

Zhihua Zhu, Zhengbo Song, Wenjie Jiao, Weijian Mei, Chunwei Xu, Qinghua Huang, Chaolun An, Jianguang Shi, Wenxian Wang, Guiping Yu, Pingli Sun, Yinbin Zhang, Jianfei Shen, Yong Song, Jun Qian, Wang Yao, Han Yang, written on behalf of AME Lung Cancer Collaborative Group

Performance of various risk prediction models in a large lung cancer screening cohort in Gdańsk, Poland—a comparative study

Marcin Ostrowski, Franciszek Bińczyk, Tomasz Marjański, Robert Dziedzic, Sylwia Pisiak, Sylwia Małgorzewicz, Mariusz Adamek, Joanna Polańska, Witold Rzyman

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

Yusuke Tomita, Bryan Oronsky, Nacer Abrouk, Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan Baker, Sunmin Lee, Jane B. Trepel

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit

Yusuke Tomita, Bryan Oronsky, Nacer Abrouk, Pedro Cabrales, Tony R. Reid, Min-Jung Lee, Akira Yuno, Jonathan Baker, Sunmin Lee, Jane B. Trepel

Comprehensive genomic profiling of combined small cell lung cancer

Jing Zhang, Liping Zhang, Jie Luo, Tao Ge, Pengyu Fan, Liangdong Sun, Likun Hou, Junqiang Li, Huansha Yu, Chunxiao Wu, Yuming Zhu, Chunyan Wu, Gening Jiang, Giancarlo Troncone, Jyoti Malhotra, Katsuhiro Okuda, Mariacarmela Santarpia, Rita Zamarchi, Taichiro Goto, Andrés F. Cardona, Jianfang Xu, Qiankun Chen, Zhonghong Zhang, Peng Zhang, written on behalf of the AME Lung Cancer Collaborative Group

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis

Giorgia Guaitoli, Marcello Tiseo, Massimo Di Maio, Luc Friboulet, Francesco Facchinetti

A nomogram prognostic model for large cell lung cancer: analysis from the Surveillance, Epidemiology and End Results Database

Gang Lin, Kang Qi, Bing Liu, Haibo Liu, Jian Li

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma

Minsu Kang, Changhee Park, Se Hyun Kim, Sock Won Yoon, Koung Jin Suh, Yu Jung Kim, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jong Seok Lee

Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial

Zhen He, Hanqiong Zhou, Junsheng Wang, Ding Li, Xudong Zhang, Pengyuan Wang, Tianjiang Ma, Yueqiang Zhang, Chuntao Tian, Yunfang Chen, Minglei Zou, Yu Han, Cong Xu, Shuxiang Ma, Lili Wang, Xuan Wu, Gongbin Chen, Qiming Wang

Review Article

Lung cancer screening: targeting the hard to reach—a review

Guido Van Hal, Paloma Diab Garcia

Challenges in the target volume definition of lung cancer radiotherapy

Susan Mercieca, José S. A. Belderbos, Marcel van Herk

Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer

Steven Bozinovski, Amanda Vannitamby, Kanishka Rangamuwa, Savreet Aujla, Hao Wang, Christian Aloe, Louis Irving, Tracy T. Leong, Daniel P. Steinfort

The radiologist’s role in lung cancer screening

Annemiek Snoeckx, Caro Franck, Mario Silva, Mathias Prokop, Cornelia Schaefer-Prokop, Marie-Pierre Revel

Immunotherapy in small cell lung cancer: one step at a time: a narrative review

Daphne W. Dumoulin, Anne-Marie C. Dingemans, Joachim G. J. V. Aerts, Jordi Remon, Dirk K. M. De Ruysscher, Lizza E. L. Hendriks

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy

Ben G. L. Vanneste, Evert J. Van Limbergen, Kobe Reynders, Dirk De Ruysscher

Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research

Eugenia Vlaskou Badra, Michael Baumgartl, Silvia Fabiano, Aurélien Jongen, Matthias Guckenberger

Immunotherapy in oncogene addicted non-small cell lung cancer

Luke McLean, Jose Luis Leal, Benjamin J. Solomon, Thomas John

Lung cancer screening and smoking cessation efforts

Dana Moldovanu, Harry J. de Koning, Carlijn M. van der Aalst

Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors

Kanishka Rangamuwa, Tracy Leong, Clare Weeden, Marie-Liesse Asselin-Labat, Steven Bozinovski, Michael Christie, Tom John, Phillip Antippa, Louis Irving, Daniel Steinfort

Lung cancer screening: who pays? who receives?—the Chinese perspective

Yang Zhang, Haiquan Chen

Should sublobar resection be offered for screening-detected lung nodules?

Alan D. L. Sihoe

Managing of screening-detected sub-solid nodules—a European perspective

Sara Ricciardi, Richard Booton, Renè Horsleben Petersen, Maurizio Infante, Marco Scarci, Giulia Veronesi, Giuseppe Cardillo

Dose and fractionation schedules in radiotherapy for non-small cell lung cancer

Lucyna Kepka, Joanna Socha

Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?

Anton Schreuder, Ernst T. Scholten, Bram van Ginneken, Colin Jacobs

Evolving target volume concepts in locally advanced non-small cell lung cancer

Ursula Nestle, Cecile Le Pechoux, Dirk De Ruysscher

Implementation of lung cancer screening: what are the main issues?

Carlijn M. van der Aalst, Kevin ten Haaf, Harry J. de Koning, for the 4-IN-THE-LUNG-RUN Consortium

Implementation of low-dose CT screening in two different health care systems: Mount Sinai Healthcare System and Phoenix VA Health Care System

Claudia I. Henschke, David F. Yankelevitz, Artit Jirapatnakul, Rowena Yip, Vivian Reccoppa, Charlene Benjamin, Tserling Llamo, Angel Williams, Simon Liu, Daniel Max, Samuel M. Aguayo, Providencia Morales, Brian J. Igel, Hamed Abbaszadegan, Peter A. Fredricks, Daniel P. Garcia, Paska A. Permana, Janet Fawcett, Samir Sultan, Lorenza A. Murphy

Latest CT technologies in lung cancer screening: protocols and radiation dose reduction

Marleen Vonder, Monique D. Dorrius, Rozemarijn Vliegenthart

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations

Roberto Ferrara, Diego Signorelli, Claudia Proto, Arsela Prelaj, Marina Chiara Garassino, Giuseppe Lo Russo

Participation in lung cancer screening

David R. Baldwin, Kate Brain, Samantha Quaife

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)

Małgorzata Łazar-Poniatowska, Artur Bandura, Rafał Dziadziuszko, Jacek Jassem

Overdiagnosis in lung cancer screening

David F. Yankelevitz, Claudia I. Henschke

Pulmonary nodule radiological diagnostic algorithm in lung cancer screening

Katarzyna Dziadziuszko, Edyta Szurowska

Managing screening-detected subsolid nodules—the Asian perspective

Masaaki Sato, Shun-Mao Yang, Dong Tian, Nakajima Jun, Jang-Ming Lee

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

Lizza E. L. Hendriks, Jordi Remon, Jessica Menis, Benjamin Besse

Controversies in the role of radiotherapy in pleural mesothelioma

Gerard G. Hanna, Thomas John, David L. Ball

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer

Boris Duchemann, Jordi Remon, Marie Naigeon, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Edouard Auclin, Aude Desnoyer, Benjamin Besse, Nathalie Chaput

Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease

Francesco Passiglia, Valeria Cetoretta, Marco De Filippis, Valerio Napoli, Silvia Novello

Exploring natural killer cell immunology as a therapeutic strategy in lung cancer

Jonas B. Hess, Kate D. Sutherland, Sarah A. Best

Thoracic radiotherapy in small cell lung cancer—a narrative review

Antonin Levy, Angela Botticella, Cécile Le Péchoux, Corinne Faivre-Finn

Preoperative and postoperative radiotherapy (RT) for non-small cell lung cancer: still an open question

Paul Van Houtte, Luigi Moretti, Florian Charlier, Martine Roelandts, Dirk Van Gestel

The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review

Alistair R. Miller, Renee Manser

Screen-detected solid nodules: from detection of nodule to structured reporting

Mario Silva, Gianluca Milanese, Roberta E. Ledda, Ugo Pastorino, Nicola Sverzellati

Holding our breath: the promise of tissue-resident memory T cells in lung cancer

Claire Marceaux, Clare E. Weeden, Claire L. Gordon, Marie-Liesse Asselin-Labat

Prophylactic cranial irradiation in SCLC

Rafal Suwinski

A narrative review of invasive diagnostics and treatment of early lung cancer

Robert Dziedzic, Tomasz Marjański, Witold Rzyman

Radiotherapy for thymic epithelial tumours: a review

Krisztian Süveg, Paul Martin Putora, Markus Joerger, Thomas Iseli, Galina Farina Fischer, Karlheinz Ammann, Markus Glatzer

Review Article

Added benefits of early detection of other diseases on low-dose CT screening

Rowena Yip, Artit Jirapatnakul, Minxia Hu, Xiangmeng Chen, Dan Han, Teng Ma, Yeqing Zhu, Mary M. Salvatore, Laurie R. Margolies, David F. Yankelevitz, Claudia I. Henschke, for the I-ELCAP Investigators

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.

Indexing

In Science Citation Index Expanded (SCIE)

In PubMed

In PMC

Publishing Information

Translational Lung Cancer Research is published by AME Publishing Company

Society for Translational Medicine (STM), Hong Kong

Endorsement

Translational Lung Cancer Research is endorsed by the Spanish Lung Cancer Group (SLCG).

The Bonnie J. Addario Lung Cancer Foundation (ALCF)

The Brazilian Society of Thoracic Surgery(SBCT)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Contact us

General editorial enquiries:

Copyright related contact:

Commercial Sales contact (Reprints, advertising, etc.):

Sponsored by

Editorial

Original Article

Protocol

Review Article

Case Report

Editorial Commentary

Letter to the Editor

Editorial on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions1

Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions1

Consensus

Review Article

Editorial

Review Articles

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Review Article

Highlighted Reports in European Lung Cancer Conference

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Original Article

Review Article

Editorial

Systematic Review and Meta-analysis

China Lung Cancer Research Highlight

Editorials

Review Articles

Ceritinib

Onartuzumab plus erlotinib

Editorial on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions¹

Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions¹